GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Y-mAbs Therapeutics Inc (NAS:YMAB) » Definitions » Equity-to-Asset

Y-mAbs Therapeutics (Y-mAbs Therapeutics) Equity-to-Asset : 0.79 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Y-mAbs Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Y-mAbs Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $100.99 Mil. Y-mAbs Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $127.87 Mil. Therefore, Y-mAbs Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.79.

The historical rank and industry rank for Y-mAbs Therapeutics's Equity-to-Asset or its related term are showing as below:

YMAB' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.7   Med: 0.82   Max: 0.93
Current: 0.79

During the past 8 years, the highest Equity to Asset Ratio of Y-mAbs Therapeutics was 0.93. The lowest was 0.70. And the median was 0.82.

YMAB's Equity-to-Asset is ranked better than
66.28% of 1563 companies
in the Biotechnology industry
Industry Median: 0.66 vs YMAB: 0.79

Y-mAbs Therapeutics Equity-to-Asset Historical Data

The historical data trend for Y-mAbs Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Y-mAbs Therapeutics Equity-to-Asset Chart

Y-mAbs Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial 0.92 0.80 0.85 0.77 0.79

Y-mAbs Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.77 0.79 0.79 0.78 0.79

Competitive Comparison of Y-mAbs Therapeutics's Equity-to-Asset

For the Biotechnology subindustry, Y-mAbs Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Y-mAbs Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Y-mAbs Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Y-mAbs Therapeutics's Equity-to-Asset falls into.



Y-mAbs Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Y-mAbs Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=100.985/127.869
=0.79

Y-mAbs Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=100.985/127.869
=0.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Y-mAbs Therapeutics  (NAS:YMAB) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Y-mAbs Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Y-mAbs Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Y-mAbs Therapeutics (Y-mAbs Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
230 Park Avenue, Suite 3350, New York, NY, USA, 10169
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas. The vast majority of the Company's product sales are generated in the United States with additional sales outside the United States in China and Israel through sublicenses and distribution agreements.
Executives
Thomas Gad director, officer: President and Chairman C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Biotech Aps Wg 10 percent owner RUNGSTED STRANDVEJ 113, RUNGSTED KYST G7 2960
Johan Wedell-wedellsborg director, 10 percent owner RUNGSTED STRANDVEJ 113, RUNGSTED KYST G7 2960
Michael J Rossi director, officer: President & CEO 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169
Vignesh Rajah officer: SVP and CMO HENRIKSHOJ 8, ROOM 4, VEDBAEK G7 DK-2950
Bo Kruse director, officer: EVP, CFO, Secy & Treas. C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Susan Laura Smith officer: Senior Vice President, CCO 5 OVERLOOK CT, LAMBERTVILLE NJ 08530
David N Gill director C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Juan Moller San Pedro Claus director, officer: Chief Executive Officer C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3500, NEW YORK NY 10169
Laura Hamill director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Mahiuddin Ahmed officer: Sr. VP and CSO C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169
Philip Karl Herman officer: Sr. VP and CCO C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169
James Healy director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Gregory S Raskin director C/O MEMORIAL SLOAN KETTERING CANCER CENT, 1275 YORK AVENUE, BOX 524, NEW YORK NY 10065
Gerard Ber director C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169

Y-mAbs Therapeutics (Y-mAbs Therapeutics) Headlines